Esperion Therapeutics (ESPR) Leases (2019 - 2025)
Esperion Therapeutics (ESPR) has disclosed Leases for 7 consecutive years, with $2.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Leases fell 47.0% year-over-year to $2.9 million, compared with a TTM value of $2.9 million through Dec 2025, down 47.0%, and an annual FY2025 reading of $2.9 million, down 47.0% over the prior year.
- Leases was $2.9 million for Q4 2025 at Esperion Therapeutics, down from $3.3 million in the prior quarter.
- Across five years, Leases topped out at $7.1 million in Q1 2024 and bottomed at $730000.0 in Q3 2022.
- Average Leases over 5 years is $3.6 million, with a median of $3.5 million recorded in 2021.
- The sharpest move saw Leases plummeted 80.35% in 2022, then soared 563.26% in 2024.
- Year by year, Leases stood at $1.9 million in 2021, then crashed by 45.42% to $1.0 million in 2022, then soared by 351.25% to $4.7 million in 2023, then rose by 17.93% to $5.5 million in 2024, then plummeted by 47.0% to $2.9 million in 2025.
- Business Quant data shows Leases for ESPR at $2.9 million in Q4 2025, $3.3 million in Q3 2025, and $4.2 million in Q2 2025.